278 related articles for article (PubMed ID: 24589084)
1. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.
Gringeri A; Leissinger C; Cortesi PA; Jo H; Fusco F; Riva S; Antmen B; Berntorp E; Biasoli C; Carpenter S; Kavakli K; Morfini M; Négrier C; Rocino A; Schramm W; Windyga J; Zülfikar B; Mantovani LG
Haemophilia; 2013 Sep; 19(5):736-43. PubMed ID: 23731246
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials.
Oladapo AO; Epstein JD; Williams E; Ito D; Gringeri A; Valentino LA
Haemophilia; 2015 Sep; 21(5):e344-58. PubMed ID: 26390060
[TBL] [Abstract][Full Text] [Related]
5. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.
Hoots WK; Ebbesen LS; Konkle BA; Auerswald GK; Roberts HR; Weatherall J; Ferran JM; Ljung RC;
Haemophilia; 2008 May; 14(3):466-75. PubMed ID: 18282155
[TBL] [Abstract][Full Text] [Related]
6. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
[TBL] [Abstract][Full Text] [Related]
7. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies.
Wyrwich KW; Krishnan S; Auguste P; Poon JL; von Maltzahn R; Yu R; Pierce GF; Mei B; Mahlangu J; von Mackensen S
Haemophilia; 2016 Nov; 22(6):866-872. PubMed ID: 27385432
[TBL] [Abstract][Full Text] [Related]
8. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
Oldenburg J; Tran H; Peyvandi F; Núñez R; Trask P; Chebon S; Mahlangu JN; Lehle M; Jiménez-Yuste V; von Mackensen S
Haemophilia; 2021 May; 27(3):398-407. PubMed ID: 33576546
[TBL] [Abstract][Full Text] [Related]
10. Interpreting important health-related quality of life change using the Haem-A-QoL.
Wyrwich KW; Krishnan S; Poon JL; Auguste P; von Maltzahn R; Yu R; von Mackensen S
Haemophilia; 2015 Sep; 21(5):578-84. PubMed ID: 25828456
[TBL] [Abstract][Full Text] [Related]
11. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
[TBL] [Abstract][Full Text] [Related]
12. Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.
Windyga J; Lin VW; Epstein JD; Ito D; Xiong Y; Abbuehl BE; Ramirez JH
Haemophilia; 2014 May; 20(3):362-8. PubMed ID: 24251442
[TBL] [Abstract][Full Text] [Related]
13. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries.
Noone D; O'Mahony B; van Dijk JP; Prihodova L
Haemophilia; 2013 Jan; 19(1):44-50. PubMed ID: 22913831
[TBL] [Abstract][Full Text] [Related]
14. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
Leissinger C; Gringeri A; Antmen B; Berntorp E; Biasoli C; Carpenter S; Cortesi P; Jo H; Kavakli K; Lassila R; Morfini M; Négrier C; Rocino A; Schramm W; Serban M; Uscatescu MV; Windyga J; Zülfikar B; Mantovani L
N Engl J Med; 2011 Nov; 365(18):1684-92. PubMed ID: 22047559
[TBL] [Abstract][Full Text] [Related]
15. FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations.
Perry D; Berntorp E; Tait C; Dolan G; Holme PA; Laffan M; Lassila R; Mumford A; Pasi J; Wilde J; Will A; Yee TT
Haemophilia; 2010 Jan; 16(1):80-9. PubMed ID: 19780845
[TBL] [Abstract][Full Text] [Related]
16. A retrospective postlicensure survey of FEIBA efficacy and safety.
Dimichele D; Négrier C
Haemophilia; 2006 Jul; 12(4):352-62. PubMed ID: 16834734
[TBL] [Abstract][Full Text] [Related]
17. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.
Sun HL; McIntosh KA; Squire SJ; Yang M; Bartholomew C; Gue DS; Camp PG; Jackson SC
Haemophilia; 2017 Nov; 23(6):877-883. PubMed ID: 28851133
[TBL] [Abstract][Full Text] [Related]
18. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.
Valentino LA
Haemophilia; 2010 Mar; 16(2):263-71. PubMed ID: 20028421
[TBL] [Abstract][Full Text] [Related]
19. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
20. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
